A Single Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 Cells in Severe Coronavirus Disease 2019 Patients is a PHASE1 clinical asset sponsored by LucasBio in COVID-19, COVID-19 (SARS-CoV-2 Infection). SEO and diligence focus: LB-DTK-COV19, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.